Cullinan Therapeutics reported a second-quarter 2026 net loss of $53.7 million and a loss per share of $0.81, both lower than the previous year. The company's six-month net loss stood at $103.37 million. The US FDA has provided positive feedback supporting a potentially registrational Phase 2 trial for CLN-049, Cullinan's FLT3xCD3 engager, in relapsed/refractory acute myeloid leukaemia. This represents a significant clinical and regulatory milestone for the company's lead programme. Despite the FDA backing, Cullinan faces challenges including zero revenue, ongoing losses, and reliance on capital markets, evidenced by a $200 million at-the-market offering filing. The company's share price has risen strongly over the past year, but financing risks remain as it advances towards registrational studies.

DelveInsight forecasts the EGFR-NSCLC market will grow at a 9.6% CAGR from 2025 to 2034, reaching $6 billion across seven major markets in 2024. The United States accounts for the largest market share. Growth drivers include approval of new therapies such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), and Sacituzumab Tirumotecan (Merck/Kelun-Biotech) in frontline and combination settings, rising therapy costs, and increasing testing rates enabling identification of more EGFR-positive patients. The emerging pipeline includes TKIs, antibody-drug conjugates, bispecifics, and gene therapies from companies including ArriVent BioPharma, Bristol-Myers Squibb, and AbbVie. Adenocarcinoma represents the highest number of histology-specific cases. Recent clinical trials show promising results, with some candidates demonstrating over 80% objective response rates in treatment-naïve patients.